Source: Eur Respir J , 49 (3) 1700146; DOI: 10.1183/13993003.00146-2017
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Emanuele Pontali, Lia D'Ambrosio, Rosella Centis, Giovanni Sotgiu, Giovanni Battista Migliori. Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline. Eur Respir J , 49 (3) 1700146; DOI: 10.1183/13993003.00146-2017

Member's Comments

No comment yet.

Related content which might interest you: Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence Source: Eur Respir J 2016; 47: 394-402 Year: 2016 Multidrug-resistant tuberculosis in children: evidence from global surveillance Source: Eur Respir J 2013; 42: 701-707 Year: 2013 Mycobacterium tuberculosis transmission from patients with drug-resistant compared to drug-susceptible TB: a systematic review and meta-analysis Source: Eur Respir J, 50 (4) 1701044; 10.1183/13993003.01044-2017 Year: 2017 WHO 2019 guidelines on drug-resistant tuberculosis treatment: based on evidence or expert opinion? Source: Eur Respir J, 55 (3) 1901935; 10.1183/13993003.01935-2019 Year: 2020 WHO guidance on multidrug-resistant tuberculosis treatment: using and communicating the evidence Source: Eur Respir J, 55 (3) 1902325; 10.1183/13993003.02325-2019 Year: 2020 An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis Source: Eur Respir J , 49 (3) 1600803; DOI: 10.1183/13993003.00803-2016 Year: 2017 Bedaquiline for the treatment of multidrug-resistant tuberculosis: another missed opportunity? Source: Eur Respir J, 49 (5) 1700738; 10.1183/13993003.00738-2017 Year: 2017 Is multidrug-resistant TB more common in children? An analysis of surveillance data Source: Annual Congress 2012 - MDR- and XDR-TB: epidemiological and public health overview Year: 2012 Multidrug-resistant tuberculosis around the world: what progress has been made? Source: Eur Respir J 2015; 45: 150-160 Year: 2015 Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis Source: Eur Respir J 2013; 42: 169-179 Year: 2013 Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis Source: Eur Respir J 2017; 49(1): 1600993; DOI: 10.1183/13993003.00993-2016 Year: 2017 Clinical and operational value of the extensively drug-resistant tuberculosis definition Source: Eur Respir J 2007; 30: 623-626 Year: 2007 Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience Source: Eur Respir J 2016; 47: 333-336 Year: 2016 Getting the best possible evidence from observational studies of treatment of multidrug-resistant tuberculosis patients Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013 Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives Source: Eur Respir Rev, 28 (152) 190035; 10.1183/16000617.0035-2019 Year: 2019 Comparative analysis of M. tuberculosis drug susceptibility tests results in new multidrug-resistant tuberculosis cases and their confirmed contacts. Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review Source: Eur Respir J, 52 (1) 1800934; 10.1183/13993003.00934-2018 Year: 2018 Extensively drug-resistant tuberculosis (XDR-TB) and multidrug-resistant tuberculosis (MDR-TB): a retrospective comparative study Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis Year: 2008 Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: epidemiology, diagnosis and treatment Source: Annual Congress 2008 - Infection year in review Year: 2008